MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)

    B. Bicknell, S. Tilley, G. Herkes, A. Liebert (, Westmead, Australia)

    Objective: To determine the effectiveness of photobiomodulation (light therapy) on MDS-UPDRS-III scores over a five-year period Background: As a progressive neurodegenerative disease, worsening of motor…
  • 2024 International Congress

    Effect of Prasinezumab on Parkinson’s Disease Motor Progression in a Long-term Open-label Extension of the PASADENA Trial

    G. Pagano, A. Monnet, A. Reyes, B. Ribba, H. Svoboda, T. Kustermann, T. Simuni, R. Postuma, N. Pavese, F. Stocchi, K. Brockmann, K. Smigorski, V. Gerbaldo, P. Fontoura, R. Doody, G. Kerchner, P. Brundin, K. Marek, A. Bonni, T. Nikolcheva (Basel, Switzerland)

    Objective: To evaluate the long-term effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part…
  • 2024 International Congress

    Changes in Gut Microbiome of Parkinson’s disease Patients using Photobiomodulation Therapy

    B. Bicknell, G. Herkes, A. Liebert, H. Kiat (, Westmead, Australia)

    Objective: To assess changes in the gut microbiome composition in a small cohort of clinical trial participants using photobiomodulation (light therapy) over a five-year period…
  • 2024 International Congress

    Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial

    J. O'Sullivan, N. Jayabalan, N. Birch, D. Mondhe, A. Lehn, R. Gordon, R. Adan (Brisbane, Australia)

    Objective: In this study, we evaluated the effect of targeted fructoligosaccharide (FOS) therapy to restore the beneficial butyrate producer Faecalibacterium prausnitzii, one the most highly reduced…
  • 2024 International Congress

    Evaluation of Infusion Site Adverse Events With Foslevodopa/Foscarbidopa in a 12-Week, Randomized Study

    S. Isaacson, R. Kirsner, O. Vaou, R. Pahwa, R. Hauser, L. Bergmann, R. Gupta, M. Shah, S. Varughese, T. Kimber (Boca Raton, USA)

    Objective: To characterize infusion site events (ISEs) in patients with advanced Parkinson’s disease (aPD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: ISEs, including local reactions and infusion…
  • 2024 International Congress

    Adaptive vs Conventional Chronic Deep Brain Stimulation: Results from a Randomized Pilot Trial in Parkinson’s Disease

    I. Isaias, S. Marceglia, L. Romito, R. Eleopra, L. Borellini, V. Levi, M. Locatelli, T. Mandat, E. Pirola, A. Ampollini, M. Lanotte, L. Lopiano, M. Zibetti, A. Bentivoglio, C. Piano, A. Izzo, F. Tamma, G. Foffani, A. Lozano, E. Moro, J. Volkmann, C. Conti, M. Arlotti, L. Krinke, L. Rossi, A. Priori (Milan, Italy)

    Objective: To assess the safety and efficacy of chronic adaptive (aDBS) and conventional (cDBS) deep brain stimulation of the subthalamic nucleus in patients with Parkinson’s…
  • 2024 International Congress

    WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson’s Disease: Study Design and Status Update

    J. Adams, A. Lerner, R. Al-Rubayie, T. Kangarloo, Y. Gong, V. Khachadourian, B. Tracey, D. Volfson, R. Lazman, J. Cosman, J. Edgerton, D. Anderson, A. Best, M. Kostrzebski, P. Auinger, C. Tarolli, M. Müller, D. Stephenson, E. Dorsey (Rochester, USA)

    Objective: To evaluate longitudinal change in WATCH-PD digital measures in a remote extension study in order to maximize learnings and inform use of digital measures…
  • 2024 International Congress

    Retention Strategies in Parkinson’s Disease Clinical Studies: Findings From a Scoping Review of Recruitment and Retention Strategies

    R. Petty, V. Agarwal, J. Allison, S. Bartolomeu Pires, M. Bartlett, T. Boey, R. Croucher, H. Collins, S. Collins, E. Davies, J. Duffen, R. Ellis-Doyle, C. Gonzalez-Robles, F. Hudson, J. Inches, L. Miller, G. Mills, S. Wonnacott, T. Foltynie, C. Carroll, S. Mullin, M. Zeissler (Plymouth, United Kingdom)

    Objective: To understand successful recruitment and retention strategies for clinical research studies in Parkinson’s disease (PD) Background: Half of all clinical trials do not reach…
  • 2024 International Congress

    Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder

    E. Brown, L. Chahine, A. Siderowf, C. Gochanour, C. Caspell-Garcia, M. Brumm, M. Marshall, C. Stanley, C. Soto, L. Concha, T. Sherer, T. Tanner, T. Simuni, K. Marek (San Francisco, USA)

    Objective: To compare the proportion of people with abnormal alpha-synuclein among groups with differing levels of certainty of REM sleep behavior disorder (RBD). Background: REM…
  • 2024 International Congress

    Distinct pattern of synaptic loss in Parkinson’s disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial

    M. Ansari, Y. Yang, S. Elliott, M. Naganawa, P. Honhar, M. Dias, S. Henry, J. Ropchan, R. Comley, N. Nabulsi, Y. Huang, R. Carson, S. Finnema, S. Nikayin, S. Tinaz, D. Matuskey, G. Sanacora, S. Holmes (New Haven, USA)

    Objective: To investigate synaptic loss in Parkinson's Disease depression (PDd) using PET and [11C]UCB-J (a marker for synaptic density) and present the initial blinded findings…
  • « Previous Page
  • 1
  • …
  • 133
  • 134
  • 135
  • 136
  • 137
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley